Cardiomyopathy Trial, Not Yet Recruiting NCT06794710 Sponsor: RenJi Hospital Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Not Yet Recruiting

NCT06794710
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged between 18 and 75 years old.
  • People who have been initially diagnosed with heart failure by a cardiology department and are scheduled to receive medication as part of their treatment.
  • People with no history of structural heart disease, and whose Framingham score (a measure of heart disease risk) is below 5 — or, if the score is 5 or above, a blockage in the heart's arteries has been ruled out through specific heart tests.
  • People whose kidneys are filtering at a rate of 50ml/min or above, as calculated using a standard formula called the Cockcroft-Gault formula.
  • People whose heart pumping function (measured as LVEF) is 50% or higher, as assessed by an ultrasound of the heart.
  • People whose heart's electrical timing measurement (QT interval) is below 470 milliseconds on a heart tracing test.
  • People who are willing and able to provide written consent to participate.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have acute or chronic kidney impairment, where the kidneys' filtering rate is below 50ml/min/1.73m².
  • People who have a history of heart-related conditions such as confirmed blocked heart arteries, heart valve disease, disease of the heart muscle, a heart condition present from birth, or heart failure.
  • People who have any reason they cannot safely undergo a cardiac MRI scan (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Meng Jiang, MD, PhD, RenJi Hospital, School of Medicine, Shanghai Jiantong University

Phone: 13788912766

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
30 May 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The Heart Failure Incidence of Rare cardiomyopathy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov